摘要
目的探讨CTCAE中血糖异常评价标准在肿瘤化疗中的应用，观察常用化疗方案引发血糖异常的发生率和相关因素。方法根据CTCAE3.0评价化疗配合糖皮质激素治疗和单独糖皮质激素治疗者的血糖异常。结果化疗配合糖皮质激素治疗病人220例，20例（9．09％）发生空腹血糖升高。34例仅使用糖皮质激素者，4例（11．76％）出现空腹血糖升高，差异无显著性（P=0．62）。影响化疗组病人空腹血糖升高的因素有化疗方案和年龄。经过1年（3-12个月，中位时间5．7个月）随访，证实化疗配合糖皮质激素治疗组2例、单纯糖皮质激素治疗组1例发生糖尿病。结论CTCAE3．0版可方便地应用于化疗中的血糖评价。
Aim To research the incidence and relevant factors ofabnormal blood sugar in common chemotherapy scheme according to CTCAE 3.0. Methods Abnormal blood sugar were evaluated in the patients treated by chemotherapy with glucocorticoid and by glucocorticoid alone according to CTCAE 3.0. Results 20 cases （9.09%） occurred hyperglycemia in 220 patients who received chemotherapy with giucocorticoid and 4 cases（ 11. 76% ） in 34 patients who received glucocorticoid（ P = 0.62）. 2 cases and l case of diabetes occurred respectively through one year follow up（ 3 - 12 months, median time 5.7 months）. The Influencing factor of hyperglycemia in chemotherapy group had chemotherapy protocol and age. Conclusions CTCAE 3.0 can be conveniently applied to the blood sugar evaluation during chemotherapy.
出处
《安徽医药》
CAS
2007年第1期62-63,共2页
Anhui Medical and Pharmaceutical Journal
